Plasma Fractionation Market (By Product: Albumin, Immunoglobulins, Coagulation Factors, Protease Inhibitors, Others; By Method: Centrifugation, Depth Filtration, Chromatography, Others; By Application: Neurology, Hematology, Oncology, Immunology, Pulmonology, Others; By End-use; Hospitals & Clinics, Clinical Research, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
The global plasma fractionation market size was valued at USD 33.31 billion in 2023 and is anticipated to reach around USD 74.07 billion by 2033, growing at a CAGR of 8.32% from 2024 to 2033. The growing prevalence of genetic diseases across the world is driving the growth of the plasma fractionation market.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. plasma fractionation market size was estimated at USD 12.82 billion in 2023 and is predicted to be worth around USD 28.98 billion by 2033 with a CAGR of 8.49% from 2024 to 2033.
North America led the global plasma fractionation market in 2023. The growth of this region is mainly driven by the growing number of plasma research institutes along with a rising number of startup companies related to plasma medicines. Moreover, the growing cases of rare diseases in countries such as Canada and the U.S. have also increased the demand for plasma medicines, thereby driving the market growth of the market. In addition, the growing prevalence of nerve and bone-related issues has also increased the demand for plasma therapies, which, in turn, drives the market growth. Also, the presence of plasma companies such as Baxter, LFB Plasma, Pall Corporation, ADMA Biologics, Inc., and some others also drives the market growth.
Asia Pacific is expected to witness the fastest rate of growth in the plasma fractionation market during the forecast period. The growth of this region is mainly driven by scientific developments and advancements in the healthcare sector in countries such as India, Japan, and China. Also, the rising initiatives from the public and private sectors for research & development related to plasma therapeutics have also boosted the market growth. Moreover, an increase in government initiatives aimed at opening plasma centers also fosters market growth. Furthermore, the presence of biopharma companies such as Grifols, Octapharma, Sanquin, CSL, Eden Biologics, and some others is also driving the growth of the market.
The plasma fractionation industry has experienced rapid developments due to advancements in healthcare sectors. Plasma fractionation is a down-streaming method that deals with separating different components of blood plasma. This process is used to convert human plasma into medicines and therapies for the treatment of different diseases. It uses various separation processes such as depth filtration, precipitation, centrifugation, and chromatography. The application of plasma fractionation has increased rapidly in various domains such as neurology, immunology, hematology, and some others due to the higher efficacy of plasma therapies than conventional medicines.
This plasma fractionation market is fragmented, with the presence of small and large market players. These market players are actively engaged in research and development activities related to plasma fractionation. Some of the most prominent market players include Boccard, Grifols, S.A., Hemarus Therapeutics Limited, ADMA Biologics, Bio Products Laboratory Ltd., Intas Pharmaceuticals Limited, LFB S.A., Merck Group, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., SK Plasma Co. Ltd, Virchow Biotech Private Limited and some others.
Report Coverage | Details |
Plasma Fractionation Market Size in 2023 | USD 33.31 Billion |
Plasma Fractionation Market Size in 2024 | USD 36.08 Billion |
Plasma Fractionation Market Size by 2033 | USD 74.07 Billion |
Plasma Fractionation Market Growth Rate | CAGR of 8.32% from 2024 to 2033 |
Largest Market | North America |
Base Year | 2023 |
Forecast Period | 2024 to 2033 |
Segments Covered | Product, Method, Application, End-use, and Regions |
Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Driver: Growing incidences of von willebrand's disease
The rising prevalence of Von Willebrand's disease has increased the demand for plasma therapy. Plasma therapies are found to be highly effective for treating Von Willebrand's disease as they help in blood clots in different parts of the human body. This, in turn, drives the growth of the plasma fractionation market. Also, several plasma-based therapies are approved by government organizations for the treatment of Von Willebrand's disease.
Restrain: High cost and unavailability of high-quality plasma
There have been several developments in the plasma fractionation industry in recent times. The research and development activities related to plasma-based products come with a high cost. Also, the availability of suitable plasma is very low, and plasma companies import plasma from different parts of the world, which is very costly. Thus, higher costs associated with plasma product manufacturing are expected to restrain the growth of the plasma fractionation market.
Opportunity: Rising investments to develop plasma fractionation
The plasma therapy industry has grown rapidly in recent times due to the rising number of rare diseases across the world. Several plasma therapy companies have started focussing on enhancing their plasma fractionation and collection capabilities. Also, some plasma product companies have started adopting strategies such as business expansions, acquisitions, and the inauguration of R&D facilities related to plasma therapeutics. Thus, growing investment related to plasma fractionation is expected to create ample growth opportunities for the plasma fractionation market players.
The centrifugation segment led the plasma fractionation market in 2023. The growth of this segment is driven by the growing application of this method for the extraction of cells from plasma. Moreover, centrifugation methods can facilitate the separation of red blood cells and white blood cells from one another or from platelets. Thus, the rising application of centrifugation for different applications boosts the growth of the market.
The chromatography will grow rapidly during the forecast period. The growth of this segment can be attributed to the growing application of chromatographic purification in the removal of plasma viruses, along with the rising use of industrial chromatography for plasma fractionation. Also, the rise in research and development activities related to the extraction of pure plasma along with albumin production has further driven the market growth. Moreover, the presence of High-performance liquid chromatography (HPLC) equipment companies such as Agilent Technologies. Welch Materials, Waters Corporation, Thermo Fisher Scientific, Waters Corporation, ArgusEye, Shimadzu Corporation, and PerkinElmer, Inc. also drive the market growth.
The immunoglobins segment dominated the plasma fractionation market in 2023. This segment is mainly driven by the rise in the number of patients suffering from melanoma and prostate cancer around the world. Also, several research and developments related to the innovation of immunoglobulin therapies, along with the rising application of immunoglobin in neurological disorders, are driving the market growth. Moreover, the presence of immunoglobins companies such as CSL Behring, Kedrion S.p.A., Takeda, Octapharma, Baxter International Inc., Biotest AG, and some others boosts the market growth.
The coagulation factors segment is projected to witness the fastest growth in the plasma fractionation market during the forecast period. The growth of this segment is mainly due to the growing application of plasma coagulation for stopping blood losses during endoscopy and treatment of gastrointestinal diseases. Moreover, the growing cases of sickle cell anemia have increased the demand for plasma coagulation, thereby driving the growth of the market.
The neurology segment dominated the plasma fractionation market in 2023. This segment is generally driven by the rise in the number of nerve patients across the world. Plasma-based medications are found to be highly effective against nervous disorders, which in turn boosts the market growth. Also, the research and advancements related to neurological sciences, along with the rising adoption of plasma therapies for the treatment of nerve problems, accelerate the growth of the market.
The oncology segment will grow at a considerable rate in the plasma fractionation market during the forecast period. The growth of this segment is generally driven by the rise in government initiatives towards cancer along with the growing application of plasma therapies for treating cancer. Moreover, the growing prevalence of cancer around the world also drives the market growth. Also, the growing adoption of plasma-assisted cancer immunotherapy and the use of cold atmospheric plasma (CAP) for treating cancer patients has also boosted the growth of the market.
The hospitals & clinics segment held the largest share of the plasma fractionation market in 2023. The growth of this segment is generally driven by the growing number of hospitals and clinics across the world. Also, growing advancements in hospital infrastructure for the treatment of auto-immune diseases drive the growth of the market. Moreover, the availability of experienced doctors in clinical settings has also increased the demand for plasma therapies for the treatment of cancer, heart diseases, and some others, thereby driving the market growth.
The clinical research segment is projected to grow rapidly in the plasma fractionation market during the forecast period. The growth of this segment can be attributed to the rising adoption of plasma therapy for the treatment of rare diseases. Moreover, rising research and development activities for the production of plasma-based therapeutics also drive the growth of the market.
Segments Covered in the Report
By Product
By Method
By Application
By End-use
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Plasma Fractionation Market
5.1. COVID-19 Landscape: Plasma Fractionation Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Plasma Fractionation Market, By Product
8.1. Plasma Fractionation Market, by Product, 2024-2033
8.1.1. Albumin
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Immunoglobulins
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Coagulation Factors
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Protease Inhibitors
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Plasma Fractionation Market, By Method
9.1. Plasma Fractionation Market, by Method, 2024-2033
9.1.1. Centrifugation
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Depth Filtration
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Chromatography
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Plasma Fractionation Market, By Application
10.1. Plasma Fractionation Market, by Application, 2024-2033
10.1.1. Neurology
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Hematology
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Oncology
10.1.3.1. Market Revenue and Forecast (2021-2033)
10.1.4. Immunology
10.1.4.1. Market Revenue and Forecast (2021-2033)
10.1.5. Pulmonology
10.1.5.1. Market Revenue and Forecast (2021-2033)
10.1.6. Others
10.1.6.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Plasma Fractionation Market, By End-use
11.1. Plasma Fractionation Market, by End-use, 2024-2033
11.1.1. Hospitals & Clinics
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Clinical Research
11.1.2.1. Market Revenue and Forecast (2021-2033)
11.1.3. Others
11.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 12. Global Plasma Fractionation Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2021-2033)
12.1.2. Market Revenue and Forecast, by Method (2021-2033)
12.1.3. Market Revenue and Forecast, by Application (2021-2033)
12.1.4. Market Revenue and Forecast, by End-use (2021-2033)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.1.5.2. Market Revenue and Forecast, by Method (2021-2033)
12.1.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.1.5.4. Market Revenue and Forecast, by End-use (2021-2033)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2021-2033)
12.1.6.2. Market Revenue and Forecast, by Method (2021-2033)
12.1.6.3. Market Revenue and Forecast, by Application (2021-2033)
12.1.6.4. Market Revenue and Forecast, by End-use (2021-2033)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2021-2033)
12.2.2. Market Revenue and Forecast, by Method (2021-2033)
12.2.3. Market Revenue and Forecast, by Application (2021-2033)
12.2.4. Market Revenue and Forecast, by End-use (2021-2033)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.2.5.2. Market Revenue and Forecast, by Method (2021-2033)
12.2.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.2.5.4. Market Revenue and Forecast, by End-use (2021-2033)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2021-2033)
12.2.6.2. Market Revenue and Forecast, by Method (2021-2033)
12.2.6.3. Market Revenue and Forecast, by Application (2021-2033)
12.2.6.4. Market Revenue and Forecast, by End-use (2021-2033)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2021-2033)
12.2.7.2. Market Revenue and Forecast, by Method (2021-2033)
12.2.7.3. Market Revenue and Forecast, by Application (2021-2033)
12.2.7.4. Market Revenue and Forecast, by End-use (2021-2033)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2021-2033)
12.2.8.2. Market Revenue and Forecast, by Method (2021-2033)
12.2.8.3. Market Revenue and Forecast, by Application (2021-2033)
12.2.8.4. Market Revenue and Forecast, by End-use (2021-2033)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2021-2033)
12.3.2. Market Revenue and Forecast, by Method (2021-2033)
12.3.3. Market Revenue and Forecast, by Application (2021-2033)
12.3.4. Market Revenue and Forecast, by End-use (2021-2033)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.3.5.2. Market Revenue and Forecast, by Method (2021-2033)
12.3.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.3.5.4. Market Revenue and Forecast, by End-use (2021-2033)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2021-2033)
12.3.6.2. Market Revenue and Forecast, by Method (2021-2033)
12.3.6.3. Market Revenue and Forecast, by Application (2021-2033)
12.3.6.4. Market Revenue and Forecast, by End-use (2021-2033)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2021-2033)
12.3.7.2. Market Revenue and Forecast, by Method (2021-2033)
12.3.7.3. Market Revenue and Forecast, by Application (2021-2033)
12.3.7.4. Market Revenue and Forecast, by End-use (2021-2033)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2021-2033)
12.3.8.2. Market Revenue and Forecast, by Method (2021-2033)
12.3.8.3. Market Revenue and Forecast, by Application (2021-2033)
12.3.8.4. Market Revenue and Forecast, by End-use (2021-2033)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2021-2033)
12.4.2. Market Revenue and Forecast, by Method (2021-2033)
12.4.3. Market Revenue and Forecast, by Application (2021-2033)
12.4.4. Market Revenue and Forecast, by End-use (2021-2033)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.4.5.2. Market Revenue and Forecast, by Method (2021-2033)
12.4.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.4.5.4. Market Revenue and Forecast, by End-use (2021-2033)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2021-2033)
12.4.6.2. Market Revenue and Forecast, by Method (2021-2033)
12.4.6.3. Market Revenue and Forecast, by Application (2021-2033)
12.4.6.4. Market Revenue and Forecast, by End-use (2021-2033)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2021-2033)
12.4.7.2. Market Revenue and Forecast, by Method (2021-2033)
12.4.7.3. Market Revenue and Forecast, by Application (2021-2033)
12.4.7.4. Market Revenue and Forecast, by End-use (2021-2033)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2021-2033)
12.4.8.2. Market Revenue and Forecast, by Method (2021-2033)
12.4.8.3. Market Revenue and Forecast, by Application (2021-2033)
12.4.8.4. Market Revenue and Forecast, by End-use (2021-2033)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.5.2. Market Revenue and Forecast, by Method (2021-2033)
12.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.5.4. Market Revenue and Forecast, by End-use (2021-2033)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.5.5.2. Market Revenue and Forecast, by Method (2021-2033)
12.5.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.5.5.4. Market Revenue and Forecast, by End-use (2021-2033)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2021-2033)
12.5.6.2. Market Revenue and Forecast, by Method (2021-2033)
12.5.6.3. Market Revenue and Forecast, by Application (2021-2033)
12.5.6.4. Market Revenue and Forecast, by End-use (2021-2033)
Chapter 13. Company Profiles
13.1. Grifols S.A.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. CSL Limited
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Takeda Pharmaceutical Company Limited
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Octapharma AG
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Kedrion S.p.A
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. LFB S.A.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Biotest AG
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Sanquin
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Bio Products Laboratory Ltd.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Intas Pharmaceuticals Ltd
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client